JP2018522859A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522859A5
JP2018522859A5 JP2017566643A JP2017566643A JP2018522859A5 JP 2018522859 A5 JP2018522859 A5 JP 2018522859A5 JP 2017566643 A JP2017566643 A JP 2017566643A JP 2017566643 A JP2017566643 A JP 2017566643A JP 2018522859 A5 JP2018522859 A5 JP 2018522859A5
Authority
JP
Japan
Prior art keywords
pyridin
pyridine
pyrazolo
carbonitrile
isopropylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017566643A
Other languages
English (en)
Japanese (ja)
Other versions
JP6843775B2 (ja
JP2018522859A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/038858 external-priority patent/WO2016210034A1/en
Publication of JP2018522859A publication Critical patent/JP2018522859A/ja
Publication of JP2018522859A5 publication Critical patent/JP2018522859A5/ja
Application granted granted Critical
Publication of JP6843775B2 publication Critical patent/JP6843775B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017566643A 2015-06-24 2016-06-23 ヘテロアリール置換のアミノピリジン化合物 Active JP6843775B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1877DE2015 2015-06-24
IN1877/DEL/2015 2015-06-24
PCT/US2016/038858 WO2016210034A1 (en) 2015-06-24 2016-06-23 Heteroaryl substituted aminopyridine compounds

Publications (3)

Publication Number Publication Date
JP2018522859A JP2018522859A (ja) 2018-08-16
JP2018522859A5 true JP2018522859A5 (enExample) 2019-07-18
JP6843775B2 JP6843775B2 (ja) 2021-03-17

Family

ID=56322320

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017566643A Active JP6843775B2 (ja) 2015-06-24 2016-06-23 ヘテロアリール置換のアミノピリジン化合物

Country Status (9)

Country Link
US (1) US10294229B2 (enExample)
EP (1) EP3313840B1 (enExample)
JP (1) JP6843775B2 (enExample)
CN (1) CN107849039B (enExample)
AR (1) AR105113A1 (enExample)
ES (1) ES2745525T3 (enExample)
TW (1) TW201718571A (enExample)
UY (1) UY36748A (enExample)
WO (1) WO2016210034A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3313844B1 (en) * 2015-06-24 2020-08-26 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
TWI763722B (zh) * 2016-10-14 2022-05-11 美商林伯士拉克許米公司 Tyk2抑制劑及其用途
TW202340194A (zh) * 2017-02-16 2023-10-16 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
CA3062602A1 (en) 2017-05-11 2018-11-15 Bristol-Myers Squibb Company Thienopyridines and benzothiophenes useful as irak4 inhibitors
MX2020003190A (es) 2017-09-22 2020-11-11 Kymera Therapeutics Inc Degradadores de proteinas y usos de los mismos.
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
TWI876442B (zh) * 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
KR102660255B1 (ko) 2018-08-13 2024-04-25 길리애드 사이언시즈, 인코포레이티드 Irak4 억제제로서의 피롤로[1,2-b]피리다진 유도체
WO2020036830A1 (en) 2018-08-13 2020-02-20 Gilead Sciences, Inc. Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors
TWI727392B (zh) 2018-08-13 2021-05-11 美商基利科學股份有限公司 噻二唑irak4抑制劑
AU2019389174A1 (en) 2018-11-30 2021-07-01 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN109836376B (zh) * 2019-04-10 2022-03-22 江苏汉阔生物有限公司 一种以2,3-吡啶二羧酸为原料制备2-氯代烟酸的方法
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
US12558427B2 (en) 2019-07-17 2026-02-24 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
JP7620611B2 (ja) 2019-07-18 2025-01-23 ブリストル-マイヤーズ スクイブ カンパニー IRAK4阻害剤として有用なピラゾロ[3,4-d]ピロロ[1,2-b]ピリダジニル化合物
WO2021011724A1 (en) 2019-07-18 2021-01-21 Bristol-Myers Squibb Company Tricyclic heteroaryl compounds useful as irak4 inhibitors
JP7573596B2 (ja) * 2019-07-23 2024-10-25 ブリストル-マイヤーズ スクイブ カンパニー Irak4阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物
EP4010317B1 (en) 2019-08-06 2024-06-19 Bristol-Myers Squibb Company Bicyclic heterocyclic compounds useful as irak4 inhibitors
CN114206874B (zh) 2019-08-13 2024-08-02 百时美施贵宝公司 可用作irak4抑制剂的双环杂芳基化合物
WO2021067967A1 (en) * 2019-10-04 2021-04-08 University Of Kentucky Research Foundation Preparation of pyrazolo[3,4-b]pyridines as antimalarials
WO2021119159A1 (en) 2019-12-10 2021-06-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CA3161878A1 (en) 2019-12-17 2021-06-24 Matthew M. Weiss Irak degraders and uses thereof
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
US12497370B2 (en) 2019-12-18 2025-12-16 Elanco Tiergesundheit Ag Isoxazoline derivatives
WO2021158495A1 (en) 2020-02-03 2021-08-12 Bristol-Myers Squibb Company Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors
JP7815127B2 (ja) * 2020-02-19 2026-02-17 ニューリックス セラピューティクス,インコーポレイテッド インターロイキン-1受容体関連キナーゼの二機能性分解剤およびその治療的使用
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
EP4161521A4 (en) 2020-06-03 2024-07-10 Kymera Therapeutics, Inc. DEUTERED IRAQ DEGRADERS AND USES THEREOF
AR124547A1 (es) 2020-12-30 2023-04-05 Kymera Therapeutics Inc Degradadores de irak y sus usos
WO2022174268A1 (en) 2021-02-15 2022-08-18 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
HUE070709T2 (hu) 2021-08-18 2025-06-28 Nurix Therapeutics Inc Interleukin-1 receptorhoz kapcsolódó kinázok kétfunkciós lebontói és terápiás alkalmazásuk
JP2024540080A (ja) 2021-10-29 2024-10-31 カイメラ セラピューティクス, インコーポレイテッド Irak4分解剤およびその合成
EP4472967A4 (en) 2022-01-31 2026-04-15 Kymera Therapeutics Inc Iraqi Degradation Agents and Their Uses

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2450769A1 (en) 2001-06-15 2002-12-27 Vertex Pharmaceuticals Incorporated 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
ES2373226T3 (es) 2002-06-28 2012-02-01 Astellas Pharma Inc. Derivado de diaminopirimidincarboxamida.
EP1590341B1 (en) 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
EP1651636A1 (en) 2003-07-10 2006-05-03 Neurogen Corporation Substituted heterocyclic diarylamine analogues
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
CN101679376A (zh) 2007-06-08 2010-03-24 拜尔农科股份有限公司 杀真菌剂杂环-嘧啶基-氨基衍生物
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
EP2361902A4 (en) 2008-11-21 2012-04-25 Astellas Pharma Inc 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG
KR101361027B1 (ko) 2008-11-28 2014-02-11 코와 가부시키가이샤 피리딘-3-카르복시아미드 유도체
CN102458402B (zh) 2009-06-12 2013-10-02 百时美施贵宝公司 用作激酶调节剂的烟酰胺化合物
BR112012010220A2 (pt) 2009-10-30 2021-02-23 Janssen Pharmaceutical N.V. piridinas fenóxi-substituídas como modulares do receptor opioide
EP2532656A1 (en) 2010-02-01 2012-12-12 Nippon Chemiphar Co., Ltd. Gpr119 agonist
AU2012249240A1 (en) 2011-04-29 2013-11-07 Icahn School Of Medicine At Mount Sinai Kinase inhibitors
WO2013106614A1 (en) * 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
EP2802579B1 (en) 2012-01-13 2016-04-13 Bristol-Myers Squibb Company Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
ES2686500T3 (es) * 2012-01-13 2018-10-18 Bristol-Myers Squibb Company Compuestos de piridilo sustituidos con heterocíclicos, útiles como inhibidores de cinasas
US9598440B2 (en) * 2012-10-08 2017-03-21 Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity
EP2922841B8 (en) 2012-11-08 2017-08-02 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
AU2013341200A1 (en) 2012-11-08 2015-07-02 Bristol-Myers Squibb Company Heteroaryl substituted pyridyl compounds useful as kinase modulators
CN104781251B (zh) 2012-11-08 2016-12-14 百时美施贵宝公司 可作为激酶调节剂的经双环杂环取代的吡啶基化合物
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
TW201609693A (zh) 2014-01-03 2016-03-16 必治妥美雅史谷比公司 雜芳基取代之菸鹼醯胺化合物
EP3313844B1 (en) 2015-06-24 2020-08-26 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds

Similar Documents

Publication Publication Date Title
RU2473549C2 (ru) Пиримидиновые соединения, композиции и способы применения
JP2017501202A5 (enExample)
CN107849039B (zh) 经杂芳基取代的氨基吡啶化合物
AU2017378943B2 (en) FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof
AU2018346712B2 (en) P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US8962596B2 (en) 5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases
JP2020050682A (ja) ドライアイおよび他の目に関連する疾患を治療するためのヤヌスキナーゼ阻害剤
JP7723666B2 (ja) 環式化合物およびその使用方法
CN105143207B (zh) 作为pde4抑制剂的取代的吡啶和取代的吡嗪化合物
JP2018524331A5 (enExample)
JP2019504821A5 (enExample)
ES2807785T3 (es) Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k
CN110300754A (zh) 吡咯并[1,2-b]哒嗪衍生物
JP2013523884A5 (enExample)
ME02595B (me) Heterociklilamini kao inhibitori pi3k
JP2014521711A5 (enExample)
EA030376B1 (ru) Азетидиновые производные пиперидин-4-ила как ингибиторы jak1
CN106061967A (zh) 经杂芳基取代的烟酰胺化合物
JP2013515729A5 (enExample)
TW201136937A (en) Imidazopyrimidine derivatives
AU2014207641A1 (en) Substituted Pyrrolopyrimidine Compounds, compositions thereof, and methods of treatment therewith
CN116262739A (zh) 含氮芳基衍生物调节剂、其制备方法和应用
CN110225907A (zh) 作为RORc调节剂的哒嗪衍生物
RU2026100792A (ru) Агонисты trem2
EA052528B1 (ru) Циклические соединения и способы их применения